Safety and Efficacy of Bimekizumab in Patients With Active Psoriatic Arthritis and Previous Inadequate Response or Intolerance to TNF-α Inhibitors
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)
Lancet 2022 Dec 05;[EPub Ahead of Print], JF Merola, R Landewé, IB McInnes, PJ Mease, CT Ritchlin, Y Tanaka, A Asahina, F Behrens, DD Gladman, L Gossec, AB Gottlieb, D Thaçi, RB Warren, B Ink, D Assudani, R Bajracharya, V Shende, J Coarse, LC CoatesFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.